Sales of Alzheimers drug Leqembi may be slow initially but could pick up in 2024

Analysts believe the Medicare registry requirement and new guidance on Leqembi's prescription label could potentially weigh on sales in the near term.

from Health and Science https://ift.tt/NbZ1xVm
https://ift.tt/Kotnp9J
https://ift.tt/etPodQj